Bunazosin

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Bunazosin
Accession Number
DB12230
Type
Small Molecule
Groups
Investigational
Description

Bunazosin has been used in trials studying the treatment of High Blood Pressure.

Structure
Thumb
Synonyms
Not Available
Product Ingredients
IngredientUNIICASInChI Key
Bunazosin Hydrochloride18V54TZ7U652712-76-2NBGBEUITCPENLJ-UHFFFAOYSA-N
Categories
UNII
9UUW4V7G2H
CAS number
80755-51-7
Weight
Average: 373.457
Monoisotopic: 373.211389749
Chemical Formula
C19H27N5O3
InChI Key
RHLJLALHBZGAFM-UHFFFAOYSA-N
InChI
InChI=1S/C19H27N5O3/c1-4-6-17(25)23-7-5-8-24(10-9-23)19-21-14-12-16(27-3)15(26-2)11-13(14)18(20)22-19/h11-12H,4-10H2,1-3H3,(H2,20,21,22)
IUPAC Name
1-[4-(4-imino-6,7-dimethoxy-3,4-dihydroquinazolin-2-yl)-1,4-diazepan-1-yl]butan-1-one
SMILES
CCCC(=O)N1CCCN(CC1)C1=NC2=CC(OC)=C(OC)C=C2C(=N)N1

Pharmacology

Indication
Not Available
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
4-MethoxyamphetamineBunazosin may decrease the vasoconstricting activities of 4-Methoxyamphetamine.Experimental, Illicit
AcebutololAcebutolol may increase the orthostatic hypotensive activities of Bunazosin.Approved, Investigational
AcepromazineBunazosin may increase the antihypertensive activities of Acepromazine.Approved, Vet Approved
AdrafinilBunazosin may decrease the vasoconstricting activities of Adrafinil.Withdrawn
AgmatineThe risk or severity of hypotension can be increased when Bunazosin is combined with Agmatine.Experimental, Investigational
AlfuzosinAlfuzosin may increase the antihypertensive activities of Bunazosin.Approved, Investigational
AlprenololAlprenolol may increase the orthostatic hypotensive activities of Bunazosin.Approved, Withdrawn
AmibegronBunazosin may decrease the vasoconstricting activities of Amibegron.Investigational
AmiodaroneAmiodarone may increase the orthostatic hypotensive activities of Bunazosin.Approved, Investigational
AmitrazBunazosin may decrease the vasoconstricting activities of Amitraz.Vet Approved
AmitriptylineBunazosin may increase the antihypertensive activities of Amitriptyline.Approved
AmlodipineThe risk or severity of hypotension can be increased when Bunazosin is combined with Amlodipine.Approved
AmoxapineBunazosin may increase the antihypertensive activities of Amoxapine.Approved
AmrinoneThe risk or severity of hypotension can be increased when Bunazosin is combined with Amrinone.Approved
AnisodamineBunazosin may decrease the vasoconstricting activities of Anisodamine.Investigational
ApomorphineBunazosin may decrease the vasoconstricting activities of Apomorphine.Approved, Investigational
ApraclonidineBunazosin may decrease the vasoconstricting activities of Apraclonidine.Approved
AranidipineThe risk or severity of hypotension can be increased when Bunazosin is combined with Aranidipine.Approved, Investigational
ArbutamineBunazosin may decrease the vasoconstricting activities of Arbutamine.Approved
ArformoterolBunazosin may decrease the vasoconstricting activities of Arformoterol.Approved, Investigational
AripiprazoleBunazosin may increase the antihypertensive activities of Aripiprazole.Approved, Investigational
ArotinololArotinolol may increase the orthostatic hypotensive activities of Bunazosin.Investigational
AsenapineBunazosin may increase the antihypertensive activities of Asenapine.Approved
AtenololAtenolol may increase the orthostatic hypotensive activities of Bunazosin.Approved
AvanafilAvanafil may increase the hypotensive activities of Bunazosin.Approved
AzelnidipineThe risk or severity of hypotension can be increased when Bunazosin is combined with Azelnidipine.Approved, Investigational
AzimilideThe risk or severity of hypotension can be increased when Bunazosin is combined with Azimilide.Investigational
BambuterolBunazosin may decrease the vasoconstricting activities of Bambuterol.Approved, Investigational
BarnidipineThe risk or severity of hypotension can be increased when Bunazosin is combined with Barnidipine.Approved
BefunololBefunolol may increase the orthostatic hypotensive activities of Bunazosin.Experimental
BencyclaneThe risk or severity of hypotension can be increased when Bunazosin is combined with Bencyclane.Experimental
BenidipineThe risk or severity of hypotension can be increased when Bunazosin is combined with Benidipine.Approved, Investigational
BenzphetamineBunazosin may decrease the vasoconstricting activities of Benzphetamine.Approved, Illicit
BepridilThe risk or severity of hypotension can be increased when Bunazosin is combined with Bepridil.Approved, Withdrawn
BetaxololBetaxolol may increase the orthostatic hypotensive activities of Bunazosin.Approved, Investigational
BevantololBunazosin may increase the antihypertensive activities of Bevantolol.Approved
BioallethrinThe risk or severity of hypotension can be increased when Bunazosin is combined with Bioallethrin.Approved, Experimental
BisoprololBisoprolol may increase the orthostatic hypotensive activities of Bunazosin.Approved
BitolterolBunazosin may decrease the vasoconstricting activities of Bitolterol.Withdrawn
BopindololBopindolol may increase the orthostatic hypotensive activities of Bunazosin.Approved
BrexpiprazoleBunazosin may increase the antihypertensive activities of Brexpiprazole.Approved, Investigational
BrimonidineBunazosin may decrease the vasoconstricting activities of Brimonidine.Approved
BromocriptineBunazosin may decrease the vasoconstricting activities of Bromocriptine.Approved, Investigational
BucindololBunazosin may increase the antihypertensive activities of Bucindolol.Investigational
BufuralolBufuralol may increase the orthostatic hypotensive activities of Bunazosin.Experimental, Investigational
BupranololBupranolol may increase the orthostatic hypotensive activities of Bunazosin.Approved
CarboxyamidotriazoleThe risk or severity of hypotension can be increased when Bunazosin is combined with Carboxyamidotriazole.Investigational
CaroverineThe risk or severity of hypotension can be increased when Bunazosin is combined with Caroverine.Experimental
CarteololCarteolol may increase the orthostatic hypotensive activities of Bunazosin.Approved
CarvedilolCarvedilol may increase the antihypertensive activities of Bunazosin.Approved, Investigational
CeliprololCeliprolol may increase the orthostatic hypotensive activities of Bunazosin.Approved, Investigational
ChlorpromazineBunazosin may increase the antihypertensive activities of Chlorpromazine.Approved, Investigational, Vet Approved
CilnidipineThe risk or severity of hypotension can be increased when Bunazosin is combined with Cilnidipine.Approved, Investigational
CinnarizineThe risk or severity of hypotension can be increased when Bunazosin is combined with Cinnarizine.Approved, Investigational
CirazolineBunazosin may decrease the vasoconstricting activities of Cirazoline.Experimental
ClenbuterolBunazosin may decrease the vasoconstricting activities of Clenbuterol.Approved, Investigational, Vet Approved
ClevidipineThe risk or severity of hypotension can be increased when Bunazosin is combined with Clevidipine.Approved, Investigational
ClonidineBunazosin may decrease the vasoconstricting activities of Clonidine.Approved
CloranololCloranolol may increase the orthostatic hypotensive activities of Bunazosin.Experimental
ClozapineBunazosin may increase the antihypertensive activities of Clozapine.Approved
CyclandelateThe risk or severity of hypotension can be increased when Bunazosin is combined with Cyclandelate.Approved
DapiprazoleBunazosin may increase the antihypertensive activities of Dapiprazole.Approved
DapoxetineDapoxetine may increase the orthostatic hypotensive activities of Bunazosin.Investigational
DarodipineThe risk or severity of hypotension can be increased when Bunazosin is combined with Darodipine.Experimental
DesipramineDesipramine may increase the orthostatic hypotensive activities of Bunazosin.Approved, Investigational
DetomidineBunazosin may decrease the vasoconstricting activities of Detomidine.Vet Approved
DexmedetomidineBunazosin may decrease the vasoconstricting activities of Dexmedetomidine.Approved, Vet Approved
DextroamphetamineBunazosin may increase the antihypertensive activities of Dextroamphetamine.Approved, Illicit
DihydroergotamineBunazosin may decrease the vasoconstricting activities of Dihydroergotamine.Approved, Investigational
DiltiazemThe risk or severity of hypotension can be increased when Bunazosin is combined with Diltiazem.Approved, Investigational
DipivefrinBunazosin may decrease the vasoconstricting activities of Dipivefrin.Approved
DipyridamoleDipyridamole may increase the hypotensive activities of Bunazosin.Approved
DL-MethylephedrineBunazosin may decrease the vasoconstricting activities of DL-Methylephedrine.Approved
DobutamineBunazosin may decrease the vasoconstricting activities of Dobutamine.Approved
DopexamineBunazosin may decrease the vasoconstricting activities of Dopexamine.Approved, Investigational
DotarizineThe risk or severity of hypotension can be increased when Bunazosin is combined with Dotarizine.Investigational
DoxazosinDoxazosin may increase the antihypertensive activities of Bunazosin.Approved
DoxepinBunazosin may increase the antihypertensive activities of Doxepin.Approved, Investigational
DoxofyllineBunazosin may decrease the vasoconstricting activities of Doxofylline.Approved, Investigational
DronedaroneBunazosin may increase the antihypertensive activities of Dronedarone.Approved
DroperidolBunazosin may increase the antihypertensive activities of Droperidol.Approved, Vet Approved
DroxidopaBunazosin may decrease the vasoconstricting activities of Droxidopa.Approved, Investigational
EfonidipineThe risk or severity of hypotension can be increased when Bunazosin is combined with Efonidipine.Approved, Investigational
EpanololEpanolol may increase the orthostatic hypotensive activities of Bunazosin.Experimental
EperisoneThe risk or severity of hypotension can be increased when Bunazosin is combined with Eperisone.Approved, Investigational
EphedraBunazosin may decrease the vasoconstricting activities of Ephedra.Approved, Nutraceutical, Withdrawn
EphedrineBunazosin may decrease the vasoconstricting activities of Ephedrine.Approved
EpinastineBunazosin may decrease the vasoconstricting activities of Epinastine.Approved, Investigational
EpinephrineBunazosin may increase the antihypertensive activities of Epinephrine.Approved, Vet Approved
ErgonovineBunazosin may decrease the vasoconstricting activities of Ergonovine.Approved
ErgotamineBunazosin may decrease the vasoconstricting activities of Ergotamine.Approved
EsatenololEsatenolol may increase the orthostatic hypotensive activities of Bunazosin.Experimental
EscitalopramBunazosin may increase the antihypertensive activities of Escitalopram.Approved, Investigational
EsmololEsmolol may increase the orthostatic hypotensive activities of Bunazosin.Approved
EtafedrineBunazosin may decrease the vasoconstricting activities of Etafedrine.Approved
EthosuximideThe risk or severity of hypotension can be increased when Bunazosin is combined with Ethosuximide.Approved
EtilefrineBunazosin may decrease the vasoconstricting activities of Etilefrine.Withdrawn
EtomidateBunazosin may decrease the vasoconstricting activities of Etomidate.Approved
FelodipineThe risk or severity of hypotension can be increased when Bunazosin is combined with Felodipine.Approved, Investigational
FendilineThe risk or severity of hypotension can be increased when Bunazosin is combined with Fendiline.Withdrawn
FenoterolBunazosin may decrease the vasoconstricting activities of Fenoterol.Approved, Investigational
Fish oilThe risk or severity of hypotension can be increased when Bunazosin is combined with Fish oil.Approved, Nutraceutical
FlunarizineThe risk or severity of hypotension can be increased when Bunazosin is combined with Flunarizine.Approved
FlupentixolBunazosin may increase the antihypertensive activities of Flupentixol.Approved, Investigational, Withdrawn
FluspirileneThe risk or severity of hypotension can be increased when Bunazosin is combined with Fluspirilene.Approved, Investigational
FormoterolBunazosin may decrease the vasoconstricting activities of Formoterol.Approved, Investigational
FostamatinibFostamatinib may increase the hypotensive activities of Bunazosin.Approved, Investigational
GabapentinThe risk or severity of hypotension can be increased when Bunazosin is combined with Gabapentin.Approved, Investigational
GallopamilThe risk or severity of hypotension can be increased when Bunazosin is combined with Gallopamil.Investigational
GuanabenzBunazosin may decrease the vasoconstricting activities of Guanabenz.Approved, Investigational
GuanfacineBunazosin may decrease the vasoconstricting activities of Guanfacine.Approved, Investigational
HexoprenalineBunazosin may decrease the vasoconstricting activities of Hexoprenaline.Approved, Withdrawn
HigenamineBunazosin may decrease the vasoconstricting activities of Higenamine.Investigational
IloperidoneBunazosin may increase the antihypertensive activities of Iloperidone.Approved
ImipramineBunazosin may increase the antihypertensive activities of Imipramine.Approved
IndacaterolBunazosin may decrease the vasoconstricting activities of Indacaterol.Approved
IndenololIndenolol may increase the orthostatic hypotensive activities of Bunazosin.Withdrawn
IndoraminIndoramin may increase the antihypertensive activities of Bunazosin.Withdrawn
IsoetarineBunazosin may decrease the vasoconstricting activities of Isoetarine.Approved
IsomethepteneBunazosin may decrease the vasoconstricting activities of Isometheptene.Approved
IsoprenalineBunazosin may decrease the vasoconstricting activities of Isoprenaline.Approved, Investigational
IsoxsuprineBunazosin may decrease the vasoconstricting activities of Isoxsuprine.Approved, Withdrawn
IsradipineThe risk or severity of hypotension can be increased when Bunazosin is combined with Isradipine.Approved, Investigational
LabetalolLabetalol may increase the antihypertensive activities of Bunazosin.Approved
LacidipineThe risk or severity of hypotension can be increased when Bunazosin is combined with Lacidipine.Approved, Investigational
LamotrigineThe risk or severity of hypotension can be increased when Bunazosin is combined with Lamotrigine.Approved, Investigational
LandiololLandiolol may increase the orthostatic hypotensive activities of Bunazosin.Investigational
LercanidipineThe risk or severity of hypotension can be increased when Bunazosin is combined with Lercanidipine.Approved, Investigational
LevetiracetamThe risk or severity of hypotension can be increased when Bunazosin is combined with Levetiracetam.Approved, Investigational
LevobetaxololLevobetaxolol may increase the orthostatic hypotensive activities of Bunazosin.Approved, Investigational
LevosalbutamolBunazosin may decrease the vasoconstricting activities of Levosalbutamol.Approved, Investigational
LidoflazineThe risk or severity of hypotension can be increased when Bunazosin is combined with Lidoflazine.Experimental
LisdexamfetamineBunazosin may increase the antihypertensive activities of Lisdexamfetamine.Approved, Investigational
LofexidineBunazosin may decrease the vasoconstricting activities of Lofexidine.Approved, Investigational
LoperamideThe risk or severity of hypotension can be increased when Bunazosin is combined with Loperamide.Approved
Magnesium sulfateThe risk or severity of hypotension can be increased when Bunazosin is combined with Magnesium sulfate.Approved, Investigational, Vet Approved
ManidipineThe risk or severity of hypotension can be increased when Bunazosin is combined with Manidipine.Approved, Investigational
MedetomidineBunazosin may decrease the vasoconstricting activities of Medetomidine.Vet Approved
MentholThe risk or severity of hypotension can be increased when Bunazosin is combined with Menthol.Approved
MephentermineBunazosin may decrease the vasoconstricting activities of Mephentermine.Approved
MepindololMepindolol may increase the orthostatic hypotensive activities of Bunazosin.Experimental
MetaraminolBunazosin may decrease the vasoconstricting activities of Metaraminol.Approved, Investigational
MethamphetamineBunazosin may decrease the vasoconstricting activities of Methamphetamine.Approved, Illicit
MethotrimeprazineBunazosin may increase the antihypertensive activities of Methotrimeprazine.Approved, Investigational
MethoxamineBunazosin may decrease the vasoconstricting activities of Methoxamine.Approved, Investigational
MethoxyphenamineBunazosin may decrease the vasoconstricting activities of Methoxyphenamine.Experimental
MethsuximideThe risk or severity of hypotension can be increased when Bunazosin is combined with Methsuximide.Approved
MethyldopaBunazosin may decrease the vasoconstricting activities of Methyldopa.Approved
MetoprololMetoprolol may increase the orthostatic hypotensive activities of Bunazosin.Approved, Investigational
MibefradilThe risk or severity of hypotension can be increased when Bunazosin is combined with Mibefradil.Investigational, Withdrawn
MidodrineBunazosin may decrease the vasoconstricting activities of Midodrine.Approved
MirabegronBunazosin may decrease the vasoconstricting activities of Mirabegron.Approved
MirodenafilMirodenafil may increase the hypotensive activities of Bunazosin.Investigational
MoxonidineBunazosin may decrease the vasoconstricting activities of Moxonidine.Approved, Investigational
NadololNadolol may increase the orthostatic hypotensive activities of Bunazosin.Approved
NaftopidilThe risk or severity of hypotension can be increased when Bunazosin is combined with Naftopidil.Investigational
NaphazolineBunazosin may decrease the vasoconstricting activities of Naphazoline.Approved
NebivololNebivolol may increase the orthostatic hypotensive activities of Bunazosin.Approved, Investigational
NefazodoneBunazosin may increase the antihypertensive activities of Nefazodone.Approved, Withdrawn
NicardipineBunazosin may increase the antihypertensive activities of Nicardipine.Approved, Investigational
NicergolineBunazosin may increase the antihypertensive activities of Nicergoline.Approved, Investigational
NifedipineThe risk or severity of hypotension can be increased when Bunazosin is combined with Nifedipine.Approved
NiguldipineBunazosin may increase the antihypertensive activities of Niguldipine.Experimental
NiludipineThe risk or severity of hypotension can be increased when Bunazosin is combined with Niludipine.Experimental
NilvadipineThe risk or severity of hypotension can be increased when Bunazosin is combined with Nilvadipine.Approved, Investigational
NimesulideThe risk or severity of hypotension can be increased when Bunazosin is combined with Nimesulide.Approved, Investigational, Withdrawn
NimodipineThe risk or severity of hypotension can be increased when Bunazosin is combined with Nimodipine.Approved, Investigational
NisoldipineThe risk or severity of hypotension can be increased when Bunazosin is combined with Nisoldipine.Approved
NitrendipineThe risk or severity of hypotension can be increased when Bunazosin is combined with Nitrendipine.Approved, Investigational
NorepinephrineBunazosin may decrease the vasoconstricting activities of Norepinephrine.Approved
NorfenefrineBunazosin may decrease the vasoconstricting activities of Norfenefrine.Experimental
NortriptylineBunazosin may increase the antihypertensive activities of Nortriptyline.Approved
NylidrinBunazosin may decrease the vasoconstricting activities of Nylidrin.Approved
OctopamineBunazosin may decrease the vasoconstricting activities of Octopamine.Experimental
OlanzapineBunazosin may increase the antihypertensive activities of Olanzapine.Approved, Investigational
OlodaterolBunazosin may decrease the vasoconstricting activities of Olodaterol.Approved
OrciprenalineBunazosin may decrease the vasoconstricting activities of Orciprenaline.Approved
OtiloniumThe risk or severity of hypotension can be increased when Bunazosin is combined with Otilonium.Experimental, Investigational
OxprenololOxprenolol may increase the orthostatic hypotensive activities of Bunazosin.Approved
OxyfedrineBunazosin may decrease the vasoconstricting activities of Oxyfedrine.Experimental
OxymetazolineBunazosin may decrease the vasoconstricting activities of Oxymetazoline.Approved, Investigational
PaliperidoneBunazosin may increase the antihypertensive activities of Paliperidone.Approved
PenbutololPenbutolol may increase the orthostatic hypotensive activities of Bunazosin.Approved, Investigational
PentoxifyllinePentoxifylline may increase the hypotensive activities of Bunazosin.Approved, Investigational
PergolideBunazosin may decrease the vasoconstricting activities of Pergolide.Approved, Investigational, Vet Approved, Withdrawn
PhendimetrazineBunazosin may decrease the vasoconstricting activities of Phendimetrazine.Approved, Illicit
PhenoxybenzamineBunazosin may increase the antihypertensive activities of Phenoxybenzamine.Approved
PhentolamineBunazosin may increase the antihypertensive activities of Phentolamine.Approved
PhenylephrineBunazosin may decrease the vasoconstricting activities of Phenylephrine.Approved
PhenylpropanolamineBunazosin may decrease the vasoconstricting activities of Phenylpropanolamine.Approved, Vet Approved, Withdrawn
PinaveriumThe risk or severity of hypotension can be increased when Bunazosin is combined with Pinaverium.Approved
PindololPindolol may increase the orthostatic hypotensive activities of Bunazosin.Approved, Investigational
PirbuterolBunazosin may decrease the vasoconstricting activities of Pirbuterol.Approved
PizotifenBunazosin may increase the antihypertensive activities of Pizotifen.Approved
Platelet Activating FactorPlatelet Activating Factor may increase the orthostatic hypotensive activities of Bunazosin.Experimental
PractololPractolol may increase the orthostatic hypotensive activities of Bunazosin.Approved
PrazosinPrazosin may increase the antihypertensive activities of Bunazosin.Approved
PrenalterolBunazosin may decrease the vasoconstricting activities of Prenalterol.Experimental
PrenylamineThe risk or severity of hypotension can be increased when Bunazosin is combined with Prenylamine.Withdrawn
ProcaterolBunazosin may decrease the vasoconstricting activities of Procaterol.Approved, Investigational
PromazineBunazosin may increase the antihypertensive activities of Promazine.Approved, Vet Approved
PropafenonePropafenone may increase the orthostatic hypotensive activities of Bunazosin.Approved
PropericiazineBunazosin may increase the antihypertensive activities of Propericiazine.Approved, Investigational
PropiomazineBunazosin may increase the antihypertensive activities of Propiomazine.Approved
PropiverineBunazosin may increase the antihypertensive activities of Propiverine.Approved, Investigational
PropranololPropranolol may increase the orthostatic hypotensive activities of Bunazosin.Approved, Investigational
ProtokylolBunazosin may decrease the vasoconstricting activities of Protokylol.Approved, Vet Approved
PseudoephedrineBunazosin may decrease the vasoconstricting activities of Pseudoephedrine.Approved
QuetiapineBunazosin may increase the antihypertensive activities of Quetiapine.Approved
QuinidineBunazosin may increase the antihypertensive activities of Quinidine.Approved, Investigational
RacepinephrineBunazosin may increase the antihypertensive activities of Racepinephrine.Approved
RactopamineBunazosin may decrease the vasoconstricting activities of Ractopamine.Vet Approved
ReproterolBunazosin may decrease the vasoconstricting activities of Reproterol.Investigational
RilmenidineBunazosin may decrease the vasoconstricting activities of Rilmenidine.Approved, Investigational
RimiterolBunazosin may decrease the vasoconstricting activities of Rimiterol.Experimental
RisperidoneBunazosin may increase the antihypertensive activities of Risperidone.Approved, Investigational
RitobegronBunazosin may decrease the vasoconstricting activities of Ritobegron.Investigational
RitodrineBunazosin may decrease the vasoconstricting activities of Ritodrine.Approved, Investigational
RomifidineBunazosin may decrease the vasoconstricting activities of Romifidine.Vet Approved
RopiniroleBunazosin may decrease the vasoconstricting activities of Ropinirole.Approved, Investigational
SalbutamolBunazosin may decrease the vasoconstricting activities of Salbutamol.Approved, Vet Approved
SalmeterolBunazosin may decrease the vasoconstricting activities of Salmeterol.Approved
SeletracetamThe risk or severity of hypotension can be increased when Bunazosin is combined with Seletracetam.Investigational
SildenafilSildenafil may increase the hypotensive activities of Bunazosin.Approved, Investigational
SilodosinSilodosin may increase the antihypertensive activities of Bunazosin.Approved
SolabegronBunazosin may decrease the vasoconstricting activities of Solabegron.Investigational
SotalolSotalol may increase the orthostatic hypotensive activities of Bunazosin.Approved
SynephrineBunazosin may decrease the vasoconstricting activities of Synephrine.Experimental
TadalafilTadalafil may increase the hypotensive activities of Bunazosin.Approved, Investigational
TalinololTalinolol may increase the orthostatic hypotensive activities of Bunazosin.Investigational
TamsulosinTamsulosin may increase the antihypertensive activities of Bunazosin.Approved, Investigational
TerazosinTerazosin may increase the antihypertensive activities of Bunazosin.Approved
TerbutalineTerbutaline may increase the orthostatic hypotensive activities of Bunazosin.Approved
TerodilineThe risk or severity of hypotension can be increased when Bunazosin is combined with Terodiline.Experimental
TertatololTertatolol may increase the orthostatic hypotensive activities of Bunazosin.Experimental
TetrahydropalmatineThe risk or severity of hypotension can be increased when Bunazosin is combined with Tetrahydropalmatine.Investigational
TetryzolineBunazosin may decrease the vasoconstricting activities of Tetryzoline.Approved
TheophyllineTheophylline may increase the hypotensive activities of Bunazosin.Approved
ThioproperazineBunazosin may increase the antihypertensive activities of Thioproperazine.Approved
ThioridazineBunazosin may increase the antihypertensive activities of Thioridazine.Approved, Withdrawn
TimololTimolol may increase the orthostatic hypotensive activities of Bunazosin.Approved
TizanidineBunazosin may decrease the vasoconstricting activities of Tizanidine.Approved, Investigational
TolazolineBunazosin may increase the antihypertensive activities of Tolazoline.Approved, Vet Approved
Tolfenamic AcidThe risk or severity of hypotension can be increased when Bunazosin is combined with Tolfenamic Acid.Approved, Investigational
TranilastThe risk or severity of hypotension can be increased when Bunazosin is combined with Tranilast.Approved, Investigational
TrazodoneBunazosin may increase the antihypertensive activities of Trazodone.Approved, Investigational
TretoquinolBunazosin may decrease the vasoconstricting activities of Tretoquinol.Experimental
TrifluoperazineBunazosin may increase the antihypertensive activities of Trifluoperazine.Approved, Investigational
TrimazosinTrimazosin may increase the antihypertensive activities of Bunazosin.Experimental
TrimebutineThe risk or severity of hypotension can be increased when Bunazosin is combined with Trimebutine.Approved
TrimethadioneThe risk or severity of hypotension can be increased when Bunazosin is combined with Trimethadione.Approved
TrimipramineBunazosin may increase the antihypertensive activities of Trimipramine.Approved
TulobuterolBunazosin may decrease the vasoconstricting activities of Tulobuterol.Investigational
UdenafilUdenafil may increase the hypotensive activities of Bunazosin.Approved, Investigational
UrapidilBunazosin may increase the antihypertensive activities of Urapidil.Investigational
VardenafilVardenafil may increase the hypotensive activities of Bunazosin.Approved
VerapamilBunazosin may increase the antihypertensive activities of Verapamil.Approved
VilanterolBunazosin may decrease the vasoconstricting activities of Vilanterol.Approved
VinpocetineThe risk or severity of hypotension can be increased when Bunazosin is combined with Vinpocetine.Investigational
WIN 55212-2The risk or severity of hypotension can be increased when Bunazosin is combined with WIN 55212-2.Experimental
XamoterolBunazosin may decrease the vasoconstricting activities of Xamoterol.Experimental
XylazineBunazosin may decrease the vasoconstricting activities of Xylazine.Vet Approved
XylometazolineBunazosin may decrease the vasoconstricting activities of Xylometazoline.Approved, Investigational
ZiconotideThe risk or severity of hypotension can be increased when Bunazosin is combined with Ziconotide.Approved
ZiprasidoneBunazosin may increase the antihypertensive activities of Ziprasidone.Approved
ZonisamideThe risk or severity of hypotension can be increased when Bunazosin is combined with Zonisamide.Approved, Investigational
ZuclopenthixolBunazosin may increase the antihypertensive activities of Zuclopenthixol.Approved, Investigational
Food Interactions
Not Available

References

General References
Not Available
External Links
PubChem Compound
2472
PubChem Substance
347828509
ChemSpider
2378
BindingDB
50088386
ChEBI
135576
ChEMBL
CHEMBL188185
Wikipedia
Bunazosin

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
4CompletedTreatmentHigh Blood Pressure (Hypertension)1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.112 mg/mLALOGPS
logP1.44ALOGPS
logP1.12ChemAxon
logS-3.5ALOGPS
pKa (Strongest Acidic)12.72ChemAxon
pKa (Strongest Basic)5.83ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count7ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area90.25 Å2ChemAxon
Rotatable Bond Count5ChemAxon
Refractivity116.07 m3·mol-1ChemAxon
Polarizability40.54 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as quinazolinamines. These are heterocyclic aromatic compounds containing a quianazoline moiety substituted by one or more amine groups.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Diazanaphthalenes
Sub Class
Benzodiazines
Direct Parent
Quinazolinamines
Alternative Parents
Dialkylarylamines / Anisoles / Aminopyrimidines and derivatives / Alkyl aryl ethers / 1,4-diazepanes / Imidolactams / Tertiary carboxylic acid amides / Heteroaromatic compounds / Amino acids and derivatives / Azacyclic compounds
show 5 more
Substituents
Quinazolinamine / Anisole / Dialkylarylamine / 1,4-diazepane / Alkyl aryl ether / Diazepane / Aminopyrimidine / Pyrimidine / Benzenoid / Imidolactam
show 18 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
Not Available

Drug created on October 20, 2016 15:41 / Updated on June 02, 2018 09:47